What is Tesamorelin?
Tesamorelin is a stabilized GHRH analogue. A licensed product exists for HIV-associated lipodystrophy in some markets. Research vials are not that medicine. All catalog material is for laboratory research use only.
Browse / Tesamorelin
Tesamorelin
Stabilized GHRH analogue
Injectable
2mg, Once daily
Once daily
APPROVED INDICATION (DRUG PRODUCT)
Overview
Key Benefits
Stabilized GHRH, Visceral-fat trial literature (licensed drug), GH/IGF-1 axis
Mechanism of Action
Daily GHRH-receptor stimulation in the licensed setting reduced visceral adipose tissue in trials. Mechanism is pituitary GH release with downstream IGF-1.
Molecular Information
- Weight
- 5135.9 g/mol
- Length
- 13 amino acids
- Type
- Tesamorelin (Growth Hormone-Releasing Hormone Analog)
- Formula
- C221H366N72O67S
Amino Acid Sequence
Human GHRH(1-44)-OH analog (44 aa; trans-3-hexenoic acid amidated C terminus)
Research directions
Lipodystrophy trials Approved indication (drug product)
- Visceral adipose endpoints
Pharmacokinetics
Peak hours
Half-life ~26 min IV / longer SC depot-like
Cleared hours
Licensed-product PK.
Literature
- Tesamorelin VAT trials — 2010 · Clinical. GHRH analogue and visceral fat.